Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.

Goki SudaJun ItoAtsushi NagasakaYoshiya YamamotoKen FuruyaMunenori OkamotoKatsumi TerashitaTomoe KobayashiIzumi TsunematsuJunichi YoshidaTakashi MeguroMasatsugu OharaNaoki KawagishiMegumi KimuraMachiko UmemuraTakaaki IzumiYoko TsukudaMasato NakaiTakuya ShoMitsuteru NatsuizakaKenichi MorikawaKoji OgawaNaoya Sakamotonull null

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2017)

This prospective, randomized, multicenter study indicated that FLV had no add-on effect when given with SMV/Peg-IFN/RBV combination therapy for genotype 1b HCV-infected patients.

Keyphrases

hepatitis c virus infection
dendritic cells
double blind
open label
immune response
drug delivery
placebo controlled
phase iii
phase ii
randomized controlled trial
study protocol